1. Home
  2. AMWD vs CDNA Comparison

AMWD vs CDNA Comparison

Compare AMWD & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Woodmark Corporation

AMWD

American Woodmark Corporation

HOLD

Current Price

$40.21

Market Cap

872.8M

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$20.96

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMWD
CDNA
Founded
1980
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
872.8M
1.0B
IPO Year
1995
2007

Fundamental Metrics

Financial Performance
Metric
AMWD
CDNA
Price
$40.21
$20.96
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$59.50
$28.00
AVG Volume (30 Days)
120.8K
780.9K
Earning Date
05-28-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.05
Revenue
$1,709,585,000.00
$48,324,000.00
Revenue This Year
N/A
$16.01
Revenue Next Year
N/A
$11.31
P/E Ratio
N/A
$431.20
Revenue Growth
N/A
18.93
52 Week Low
$35.51
$10.96
52 Week High
$72.16
$23.24

Technical Indicators

Market Signals
Indicator
AMWD
CDNA
Relative Strength Index (RSI) 38.20 56.81
Support Level $37.44 $15.07
Resistance Level $42.58 $21.20
Average True Range (ATR) 1.76 1.67
MACD -0.02 0.07
Stochastic Oscillator 2.25 63.26

Price Performance

Historical Comparison
AMWD
CDNA

About AMWD American Woodmark Corporation

American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: